Develop and manufacture biotherapeutics that address significant medical needs.
H.R. 3962, Affordable Health Care for America Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics.
S. 1796, America's Healthy Future Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics.
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics. H.R. 3590 , the Patient Protection and Affordable Care Act of 2009 - authorization for comparative effectiveness research.
S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research.
H.R. 3962, Affordable Health Care for America Act of 2009 - authorization for comparative effectiveness research.
S. 1796, America's Healthy Future Act of 2009 - authorization for comparative effectiveness research. H.R. 3962, Affordable Health Care for America Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics.
S. 1679, the Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics. S. 1796, America's Healthy Future Act - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research.
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research. H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics.
H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics.
H.R. 3962, Affordable Health Care for America Act - FDA approval of follow-on biologics and length of data exclusivity period.
S. 1679, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program.
S. 1796, America's Healthy Future Act of 2009 - Medicare and Medicaid reimbursement issues, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit.
S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.
MMM - Medicare/Medicaid MED - Medical/Disease Research/Clinical Labs HCR - Health Issues PHA - Pharmacy
11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
TARPLIN STRATEGIES LLC
975 F Street NW Suite 500, Washington, DC, 20004, US
RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families)
and Families and Families and Families and Families